Development of replicative and nonreplicative hepatitis B virus vectors

Gene Therapy

Volumn 4, Issue 12, 1997, Pages 1330-1340

  Chaisomchit, S ^a   Tyrrell, D L J ^a   Chang, L J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Gene therapy; HBV; Liver; tat; Vector

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; MESSENGER RNA; POL PROTEIN; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CHICKEN; CONTROLLED STUDY; ENZYME ASSAY; EXPRESSION VECTOR; FRAMESHIFT MUTATION; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATOBLASTOMA; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; UTERINE CERVIX CARCINOMA; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

GALLUS GALLUS; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031464530     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300544     Document Type: Article

References (49)

1. Wilson JM, Johnson D, Jefferson D, Mulligan R. Correction of the genetic defect in hepatocyte from the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1988; 85: 4421-4425.
2. Grossman M, Raper SE, Wilson JM. Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. Hum Gene Ther 1992; 3: 501-510.
3. Conelly S et al. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996; 7: 183-195
4. Smith TAG et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
5. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1995; 91: 2353-2357.
6. Herz J, Gerard RD. Adertovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816.
7. Li J et al. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995; 95: 768-773.
8. Kass-Eisler A et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1994; 1: 395-402.
9. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene therapy 1995; 2: 107-115.
10. Kozarsky KF et al In vivo correction of low density lipoprotein receptor deficiency in the Watanabe inheritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13701.
11. Vrancken-Peeters M-JTFD, Lieber A, Perkins J, Kay MA. Method for multiple portal vein infusions in mice: quantification of adenovirus-mediated hepatic gene transfer. BioTechniques 1996; 20: 278-285.
12. Loser P, Sandig V, Kirillova I, Strauss M. Evaluation of HBV promoters for use in hepatic gene therapy. Biol Chem Hoppe-Seyler 1996; 377: 187-193.
13. Ganem D, Varmus HE. The molecular biology of hepatitis B viruses. Ann Rev Biochem 1987; 56: 651-693.
14. Nassal M, Schaller H. Hepatitis B virus replication. Trends Microbiol 1993; 1: 221-228.
15. Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator J Med Virol 1992; 36: 101-117.
16. Bartenschlager R, Schaller H. The amino-terminal domain of the hepadnaviral P-gene encodes, the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J 1988; 7: 4185-4192.
17. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity J Virol 1990; 64: 613-620.
18. Schaller H, Fischer M. Transcriptional control of hepadnavirus gene expression. Curr Top Microbiol Immunol 1991; 168: 21-39.
19. Chang L-J, Hirsch RC, Ganem D, Varmus HE. Effects of insertional and point mutations on the functions of the duck hepatitis B virus pulymerase. J Virol 1990; 64: 5553-5558.
20. Beames B, Lanford RE. Insertions within the hepatitis B virus capsid protein influence capsid formation and RNA encapsidation J Virol 1995; 69: 6833-6838.
21. Faruqi AF et al. Replication-defective missense mutations within the terminal protein and spacer/intron regions of the polymerase gene of human hepatitis B virus. Virology 1991; 183: 764-768.
22. Machein U et al. Deletion and insertion mutants of HBsAg particles. Arch Virol 1992; 4 (Suppl.): 133-136.
23. Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 1994; 199: 292-300.
24. Nakatake H et al. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology 1993; 95: 305-314.
25. Bartenschlager R, Junker-Niepmann M, Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol 1990; 64: 5324-5332.
26. Hirsch RC et al. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature 1990; 344: 552-555.
27. Li JS et al. Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region. J Virol 1989; 63, 4965-4968.
28. Siddiqui A et al. trans-Activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 1989; 169: 479-484.
29. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly Proc Natl Acad Sci LISA 1991; 88: 1059-1063
30. Bruss V, Vieluf K Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol 1995; 69: 6652-6657.
31. Strauss M. Liver directed gene therapy: prospects and problems. Gene Therapy 1994; 1: 156-164.
32. Patel NU, Jameel S, Isom H, Siddiqui A. Interactions between nuclear factors and the hepatitis B virus enhancer. J Virol 1989; 63: 5293-5301.
33. Jameel S, Siddiqui A. The human hepatitis B virus enhancer requires trans-acting cellular factor(s) for activity. Mol Cell Biol 1986; 6: 710-715.
34. Sandig V et al. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 1996; 3: 1002-1009.
35. Condreay LD et al. Efficiency duck hepatitis B virus production by an avian liver tumor cell line. J Virol 1990; 64: 3249-3258.
36. Hirsch RC, Loeb DD, Pollack JR, Ganem D. cis-Acting sequence required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol 1991; 65, 3309-3316.
37. Junker-Neipmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990; 9: 3389-3396.
38. Chang L-J, Ganem D, Varmus HE. Mechanism of translation of the hepadnaviral polymerase (P) gene. Proc Natl Acad Sci USA 1990; 87: 5158-5162.
39. Obert S et al. A spliced hepadnavirus RNA that is essential for virus replication. EMBO J 1996; 15: 2565-2574.
40. Wu H-L et al. Characterization and genetic analysis of alternatively spliced transcripts of hepatitis B virus in infected human liver tissues and transfected HepG2 cells. J Vitrol 1991; 65: 1680-1686.
41. Petit M-A, Capel F, Dubanchet S, Mabit H. PreS1-specific proteins as potential receptors for hepatitis B virus in human hepatocytes. Virology 1992, 187: 211-222.
42. Klingmuller U, Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol 1993; 67: 7414-7422.
43. Horwich AL, Furtak K, Pugh J, Summers J. Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 Cells. J Virol 1990; 64: 642-650.
44. Robinson D, Elliott JF, Chang L-J. Retroviral vector with a CMVIE/HIV-TAR Hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat. Gene Therapy 1995; 2: 269-278.
45. Picard V, Ersdal-Badju E, Lu A, Bock SC. A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase. Nucleic Acids Res 1994; 22: 2587-2591.
46. Seifer M, Heerman KH, Gerlich WH. Replication of hepatitis B virus in transfected nonhepatic cells. Virology 1990; 179: 300-311.
47. Persing DH, Varmus HE, Garnem D. Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 1986; 234: 1388-1391.
48. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press: New York, 1989, pp 9.31-9.57.
49. Tsang SS et al. Loss of resolution in gel electrophoresis of RNA: a problem associated with the presence of formaldehyde gradients. BioTechniques 1993; 14: 380-381.